Levogenix

Lansoprazole, the active ingredient in Levogenix, is a proton pump inhibitor presented as an oral tablet for oral use. It reduces gastric acid production and is used to treat conditions such as gastro‑esophageal reflux disease, peptic ulcer disease, erosive esophagitis, and as part of Helicobacter pylori eradication regimens in adult patients.

GNH USA supplies Levogenix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide. The company adheres to European Union quality standards and provides reliable sourcing for clinical and retail settings.

Levogenix (lansoprazole) is employed to manage acid‑related gastrointestinal disorders. It acts on the gastric proton pump to lower acid secretion, benefiting several conditions.

- Gastro‑esophageal reflux disease (GERD): reduces acid exposure and promotes healing of the esophageal lining. - Peptic ulcer disease: facilitates ulcer healing by decreasing gastric acidity. - Erosive esophagitis: alleviates mucosal damage caused by refluxed acid. - Helicobacter pylori eradication (in combination therapy): enhances the effectiveness of antibiotic regimens by providing a less acidic environment.

Adverse reactions may occur with any medication. The following lists reported events associated with lansoprazole use.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: loose stools, sometimes watery. - Nausea: feeling of queasiness or upset stomach. - Abdominal pain: discomfort or cramping in the stomach area. - Flatulence: increased gas production. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis presenting with diarrhea. - Severe allergic reactions: anaphylaxis, angioedema, or skin rash. - Interstitial nephritis: kidney inflammation with reduced function. - Elevated liver enzymes: signs of hepatic stress. - Long‑term bone fracture risk: decreased calcium absorption potentially leading to fractures.

Before initiating therapy, consider the following safety measures.

- Assess renal function: adjust use in patients with severe impairment. - Review hepatic status: use with caution in moderate liver disease. - Monitor for drug interactions: especially with clopidogrel, atazanavir, and methotrexate. - Limit duration of use: avoid indefinite therapy without periodic reassessment. - Discontinue before certain surgeries: evaluate need for acid suppression peri‑operatively. - Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Lansoprazole can affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, increasing cardiovascular risk. - Atazanavir: decreased absorption, leading to sub‑therapeutic HIV control. - HIV protease inhibitors (e.g., ritonavir): altered plasma levels. - Methotrexate: increased toxicity due to reduced clearance.

Moderate Interactions (Monitor Closely): - Warfarin: possible INR elevation, requiring dose adjustment. - Digoxin: increased serum concentration, risk of toxicity. - Phenytoin: reduced levels, potentially decreasing seizure control. - Fluconazole: may raise lansoprazole concentrations, monitor for side effects.